GIGABYTE
24.6.2021 12:47:12 CEST | Business Wire | Press release
GIGABYTE, a world leader in computer technology, is excited to be part of MWC (Mobile World Congress) to present its products and insights on Edge computing , and be joined by innovators and decision-makers who will shape the future of 5G deployments and 6G planning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005477/en/
GIGABYTE presents a series of servers that are “short and sweet”, and available in either x86 or Arm platforms to support diverse applications. Not only are these Edge servers shortened to depths ranging from only 400-600mm to fit in more environments for telecom deployments, but also ready to serve as HPCs to handle challenging workloads for AI and data processing that are closer to users’ applications.
- E152-ZE0 - Supports 3rd Gen AMD EPYC 7003 and 7002 processors, is extremely short with 400mm in depth, comes with 8 DIMM slots, and supports two U.2 NVMe SSDs. The E152 chamber for dual-slot GPUs can also be used for two single-slot cards operating at Gen4 x16, and two low-profile expansion slots on the front to provide user with powerful performance and flexibility for implementation.
- E162-220 - Designed for 3rd Gen Intel Xeon Scalable processors and has 16 DIMMs for industry standard 8-channel memory, and supports two U.2 SSDs and three M.2 connectors onboard with Gen4 PCIe transmission. All I/Os are designed in the same direction, making it suitable not only for installation in data centers, but also for deployment in base stations to provide 5G MEC or edge computing for services.
- E251-U70 - The first GIGABYTE edge server designed for 2nd Gen Intel Xeon Scalable processors, supporting six 2.5” SATA/SAS bays on the front-left, and a dual-slot GPU plus a FHFL single-slot card on the front-right. Notably, this server was chosen by NVIDIA Aerial Developer Kit for development and deployment of vRAN stack. E251-U71, a SKU variant that is NEBS design ready, is designed for extreme conditions such as high temperature, humidity or altitude.
- E252-P30 – Built for workloads on Arm architecture and uses Ampere Altra processors with up to 80 cores and 16 DIMMS for a wealth of possibilities in the cloud, the server is a viable option when considering TCO. It has six SSDs bays and lots of expansion slots for low-profile accelerators, storage, or networking.
The “short”ness of GIGABYTE Edge servers’ chassis and the “sweet”ness of its performance capabilities will prove to be indispensable equity in telecommunications, as the success in 5G deployments demands a widespread of MEC networks that are both closely-and-intelligently-connected.
GIGABYTE is an engineer, visionary, and leader in the tech world that uses its hardware expertise, patented innovations, and industry leadership to create, inspire, and advance. With over 30 years of celebrated experience, GIGABYTE is pleased to be the backbone of the IT infrastructure and provide the industry with data center expertise and cutting-edge server products that can accelerate scientific and technological breakthroughs.
https://www.mwcbarcelona.com/exhibitors/gigabyte-technology
See more presentations: https://www.gigabyte.com/Tech-Tune-In
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005477/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom